Tiziana Life Sciences Stock News

Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022. The biotechnology company's interi

Tiziana Life Sciences Ltd (NASDAQ:TLSA) (Tiziana Life Sciences Ltd (NASDAQ:TLSA)) has announced the initiation of a program to develop intranasal Foralumab as a treatment or prevention method for type

Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillion The role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab dampens activated microglia NEW YORK, April 13, 2023 -- Tiziana Life Sciences Ltd.&nbs...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced plans to investigate intranasal foralumab for the treatment of Long COVID, work which is supported by foralumab's well-established role in de-acti

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that poster presentations on intranasal foralumab are being presented at the ‘Preserving the Brain' scientific conference and exhibit at the Fon

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported “exciting” pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody (mAb) in a model of intracerebral hemorrhage (hemorrhagi

  Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference in Sweden   Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer's disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments...

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that positive data from a study of intranasal anti-CD3 monoclonal antibody (mAb) in an animal model of Alzheimer's disease will be presented at an

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has received feedback based on the US Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of intranasal fora

Tiziana Life Sciences Ltd (NASDAQ:TLSA). said it has received positive coverage in an article on Forbes which highlighted foralumab, its unique intranasal monoclonal antibody currently in clinical de

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced a publication in the preeminent journal Proceedings of the National Academy of Sciences (PNAS) that illustrates the immunological basis of the me

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the Investigational New Drug (IND) application filing for its milciclib treatment in combination with gemcitabine for non-small cell lung cancer

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has hailed news of an improvement in a multiple sclerosis patient being treated with intranasal foralumab in a clinical study. This second expanded access pati

Tiziana Life Sciences Ltd (NASDAQ:TLSA) highlighted milestones from the first six months of 2022 as the company advances its pipeline of next-generation therapeutics and diagnostics for oncology and

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced completion of the in-life portion of a 13-week, Good Laboratory Practice (GLP) foralumab intranasal pre-clinical study in transgenic HuGEMM CD3 m